Genzyme Corporation

Bayer Pharmaceuticals Corporation

Bayer Healthcare LLC

Takeda Pharmaceutical Company Limited

Bayer Corporation

Aerovance, Inc.

Bayer Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Shire-nps Pharmaceuticals, Inc.

Genzyme Coporation

Morphosys Ag

Shire Human Genetic Therapies, Inc.

Clark Qun Pan

Huawei Qiu

James E Stefano

Qun Zhou

Robert J Miller

James Whelan

Pradeep K Dhal

Luis Z Avila

Diego A Gianolio

Kevin B Clairmont

Bo Chen

Yunxiang Zhu

Michael Reardon

Patrick Finn

Lauren Young

Paul A Konowicz

Xiaoyang Zheng

John Harrahy

Duncan E Paterson

Andreas Peer

Joseph P Kutzko

Timothy E Weeden

Michael A Perricone

John Lyle Dzuris

Andrea E Edling

Andreas Knorr

Claudia Hirth-Dietrich

Ronnie Rong Wei

Angela Norton

Thomas Barnett

John E Murphy

Julie Bird

Deqian Wang

Jonathan S Strauss

Baisong Mei

Jeffrey M Greve

Andreas Menrad

Armen B Shanafelt

Gloria Matthews

Manami Tsutsumi

Sunghae Park

Kevin Holmes

Steve Roczniak

Magali Mathieu

Srinivas Shankara

Stephanie Yung

Thomas Allen Miller

Muthuraman Meiyappan

Bettina Strack-Logue

Bohong Zhang

Andrea Iskenderian

Michael Schauer

Hendri Tjandra

Jianmin Chen

Liang Tang

Sabine Kraft

Barbara Krebs

Malinda Longphre

Daniel Snell

Gina Lacorcia

Adrian Tomkinson

Aaron Moulin

Rongxin Shi

Chuan Shen

Sujit Jain

Michael O'Callaghan

Benjamin Kebble

Teresa Mo-Fun Wong

Wei Wang

David C Boisvert

Kathy Delaria

Wayne A Froland

Drew N Kelner

Michael L Dumas

Yu-chang John Wang

Bryan James Goodwin

Geoffrey Y Akita

David Bruce Lloyd

Clément Olivier

Jun Hu

Brian Dwyer

Paul McLean

Robert Miller

Bryan Goodwin

David Lloyd

Rebecca Sendak

Elise Burmeister-Getz

Lihui Hou

Andreas M Knorr

Ronnie Wei

Michael R Reardon

Duncan Patterson

Zhiqiang Jia

The invention relates to parathyroid hormone (PTH) variants and pharmaceutical compositions comprising same. The invention further relates to PTH compositions with improved serum half-life and peak-trough ratios, and methods of controlling serum calcium levels with the PTH variants and compositions of the invention. The invention further relates to methods of treating hypoparathyroidism and/or hypocalcemia due to hypoparathyroidism with the PTH variants and compositions of the invention.

Parathyroid hormone variants

Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.

Oligosaccharide-protein conjugates

The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Site-specific antibody-drug conjugation through glycoengineering

An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.

scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity

Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Hyperglycosylated binding polypeptides

The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Site-specific glycoengineering of targeting moieties

The invention relates to an affinity resin functionalized with small molecule inhibitors of glycoside-cleaving enzymes, e.g., &#x3b1;-galactosidase A (&#x3b1;-Gal A), glucocerebrosidase (GCB), &#x3b2;-galactosidase, and acid alpha-glucosidase (GAA), and a method for purifying glycoside-cleaving enzymes produced in a cell line using the small molecule inhibitor-functionalized affinity resin.

Affinity purification of glycosidase-cleaving enzymes

GLP-2 analogs, such as teduglutide, and fusion proteins of GLP-2 with immunoglobulin are administered before, during or after surgery, particularly resection of the small intestine. When short bowel syndrome develops after surgical resection of the small intestine, parenteral nutrition is usually necessary to compensate for reduced absorption of water and nutrients across the small intestine. GLP-2 analogs and GLP-2 fusion proteins promote growth of small intestine, improve nutrient absorption and can reduce the need for parenteral nutrition after surgery.

GLP-2 analogs and peptibodies for administration before, during or after surgery

An scFv-Fc dimer binds and neutralizes TGF&#x3b2;1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF&#x3b2;1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.

scFv-Fc dimers that bind transforming growth factor-&#x3b2;1 with high affinity, avidity and specificity

The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.

Anti-&#x3b1;&#x3b2;TCR antibody

Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine or threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Fc containing polypeptides with altered glycosylation and reduced effector function

Growing community of inventors

Cambridge, MA, United States of America

Clark Qun Pan